
Caring for the world, one person at a time.
China Solid Tumor NPP Lead (Associate Director)
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and Med Tech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at jnj.com.
As guided by Our Credo, Johnson & Johnson is responsible to our employees who work with us throughout the world. We provide an inclusive work environment where each person is considered as an individual. At Johnson & Johnson, we respect the diversity and dignity of our employees and recognize their merit.
Job Function:
Marketing
Job Sub Function:
Strategic Marketing
Job Category:
People Leader
All Job Posting Locations:
Beijing, China, Shanghai, China
Job Description:
Job Title:
Solid Tumor China NPP Lead/Associate Strategic Marketing Director
Reporting Line
Reports to: APSO Solid Tumor TA Lead
Matrix collaboration with: APSO, Op Co Solid Tumors teams, China R&D (CCT), Medical, Market Access, BD, and Commercial Operations
Purpose of the Role
The China Solid Tumors Strategic Marketing – New Product Planning Lead is accountable for shaping and driving the long‑term pipeline and portfolio strategy for Solid Tumour oncology in China, from early clinical stages through pre‑launch readiness.
This role serves as the strategic “bridge” between global asset development and China’s unique market needs, ensuring future assets, indications, and business models are fit‑for‑China, competitively differentiated, and launch‑ready. The role leads China NPP strategy across key solid tumour disease areas and plays a critical role in influencing global development priorities, lifecycle strategy, and portfolio investment decisions.
Key Responsibilities
1. China Solid Tumours Pipeline & Portfolio Strategy
-
Own and drive the China Solid Tumours NPP strategy, spanning early to late‑stage assets and indications.
-
Define China‑specific strategic imperatives, disease area priorities, and portfolio sequencing aligned to unmet medical need and commercial opportunity.
-
Lead pipeline sufficiency and portfolio gap analysis versus current and future competitive landscapes in China.
-
Develop and articulate clear China value narratives for pipeline assets to support governance, prioritization, and investment decisions.
2. Early Asset & Indication Shaping
-
Influence Target Product Profiles (TPPs), indication sequencing, and clinical development strategies to optimize China relevance.
-
Partner closely with China Compound Team (CCT), APSO DAS lead, and Medical Affairs to ensure early integration of commercial insights.
-
Provide strategic input at key global development milestones (pre‑IND, Phase I–III, lifecycle extensions).
-
Identify China‑specific opportunities including biomarkers, precision medicine strategies, combination approaches, and novel access models.
3. Pre‑Launch & Launch Excellence Readiness
-
Lead China pre‑launch strategic planning for priority solid tumour assets, ensuring seamless transition from NPP to inline teams.
-
Define future launch archetypes, success metrics, and critical enablers (diagnostics, patient pathways, ecosystem readiness).
-
Ensure early alignment across Commercial, Medical, Market Access, and Operations on launch ambition and execution model.
4. Cross‑Functional & Global Leadership
-
Act as the China strategic interface to global and regional Solid Tumours teams.
-
Lead and influence complex, matrixed cross‑functional teams without direct authority.
-
Partner with Business Development to assess external opportunities, collaborations, and pipeline expansion options relevant to China.
-
Represent China perspectives in global governance forums, ensuring China’s voice is clearly articulated and influential.
5. Strategic Planning & Governance
-
Drive China Solid Tumours long‑range strategic planning (LRFP, BP) from a pipeline and portfolio perspective.
-
Support senior leadership with high‑quality strategic insights, scenario planning, and decision frameworks.
-
Ensure all activities are compliant with internal governance, ethics, and regulatory requirements.
Key Stakeholders
-
AP Solid Tumours DAS & Asset Teams
-
China Oncology Leadership Team
-
China R&D / CCT
-
Medical Affairs, Market Access, Commercial Excellence
-
Business Development & Strategic Insights
Qualifications & Experience
Required
-
Bachelor’s degree required; MBA, PhD, PharmD, or MD strongly preferred
-
Extensive experience in oncology strategic marketing, NPP, portfolio strategy, or commercial strategy
-
Strong understanding of China oncology market dynamics, including policy, access, and competitive environment
-
Proven ability to influence global development and lifecycle strategy without direct reporting lines
-
Experience across early and late‑stage pipeline assets
Preferred
-
Solid tumour therapeutic area expertise (e.g., lung, GU, GI, bladder, CRC, breast, head & neck)
-
Experience working in matrixed global–regional–local organizations
-
Exposure to precision medicine, diagnostics, or novel modalities
-
Strong strategic storytelling and executive communication skills
Critical Capabilities
-
Enterprise‑level strategic thinking
-
Strong commercial and clinical acumen
-
High influence and stakeholder management capability
-
Comfort with ambiguity and early‑stage decision‑making
-
Ability to translate complexity into clear strategic choices
Success Measures
-
Strength and clarity of China Solid Tumours pipeline strategy
-
Degree of China influence on global asset and indication decisions
-
Quality of pre‑launch readiness for priority assets
-
Leadership impact across cross‑functional and global stakeholders
Required Skills:Preferred Skills:
Brand Marketing, Brand Marketing, Brand Positioning Strategy, Business Alignment, Business Storytelling, Business Valuations, Cross-Functional Collaboration, Customer Intelligence, Data Analysis, Data-Driven Decision Making, Developing Others, Digital Strategy, Execution Focus, Financial Analysis, Go-to-Market Strategies, Inclusive Leadership, Industry Analysis, Leadership, Market Research, Negotiation, Problem Solving, Product Development Lifecycle, Product Portfolio Management, Product Strategies, Program Management {+ 2 more}
閲覧数
0
応募クリック
0
Mock Apply
0
スクラップ
0
類似の求人

Strategy Lead
Payoneer · Shanghai, China

Lead Athlete
Nike · Jinan, China Mainland

Supply Chain Excellence Lead
PPG Industries · Shanghai, Shanghai, China

Sr Offering Manager
Honeywell · Shanghai, China, CN

(Associate) Director, Ethics and Compliance Internal Investigations, China
Eli Lilly · China, Shang Hai-上海
Johnson & Johnsonについて

Johnson & Johnson
PublicJohnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange.
10,001+
従業員数
New Brunswick
本社所在地
$400B
企業価値
レビュー
2件のレビュー
3.3
2件のレビュー
ワークライフバランス
4.0
報酬
2.5
企業文化
2.5
キャリア
2.0
経営陣
2.0
65%
知人への推奨率
良い点
Good work-life balance
Strong R&D environment
Potential for fulfilling work
改善点
Significant pay cuts
Employees feel unimportant
Unclear role expectations
給与レンジ
2,250件のデータ
Mid/L4
Senior/L5
Director
Mid/L4 · Manager
338件のレポート
$155,591
年収総額
基本給
$137,488
ストック
-
ボーナス
$18,103
$106,549
$229,934
面接レビュー
レビュー6件
難易度
3.0
/ 5
期間
14-28週間
面接プロセス
1
Application Review
2
HR Screen
3
Personality/Assessment Test
4
Virtual/Video Interview
5
Hiring Manager Interview
6
Offer
よくある質問
Behavioral/STAR
Technical Knowledge
Culture Fit
Past Experience
最新情報
FDA Decisions Put Johnson & Johnson’s Growth And Valuation In Focus - Yahoo Finance
Yahoo Finance
News
·
1w ago
Directional Asset Management Invests $3.02 Million in Johnson & Johnson $JNJ - MarketBeat
MarketBeat
News
·
1w ago
Johnson & Johnson Gains Focus In S&P 500 today Watch - Kalkine Media
Kalkine Media
News
·
1w ago
Johnson & Johnson Shareholders Back Board, Pay at 2026 Meeting - TipRanks
TipRanks
News
·
1w ago